IDH2 and acute myeloid leukemia: While IDH2 mutated AML patients responded significantly better with an overall response rate of 74% vs 36% (p = 0.0003), overall survival was similar between the treatment groups, likely influenced by patients progressing on AZA receiving the already approved enasidenib as a second-line treatment [105].